Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | GHSR | Q92847 | 3/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 5/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8135311 | 1.00 | HDAC8 (0.54) | HDAC8HRH3GHSRCTSDTACR2 | |
| SCHEMBL1598687 | 0.97 | HDAC8 (0.57) | HDAC8HRH3GHSRCTSDTACR2 | |
| SCHEMBL7304234 | 0.97 | HDAC8 (0.57) | HDAC8HRH3GHSRCTSDTACR2 | |
| SCHEMBL1673516 | 0.97 | HDAC8 (0.57) | HDAC8HRH3GHSRCTSDTACR2 | |
| SCHEMBL30637590 | 0.92 | OPRM1 (0.55) | OPRM1OPRD1OPRK1CXCR4 | |
| SCHEMBL30637599 | 0.92 | OPRM1 (0.55) | OPRM1OPRD1OPRK1CXCR4 | |
| SCHEMBL30637559 | 0.92 | OPRM1 (0.55) | OPRM1OPRD1OPRK1CXCR4 | |
| SCHEMBL30637487 | 0.92 | OPRM1 (0.55) | OPRM1OPRD1OPRK1CXCR4 | |
| Acetic Acid SCHEMBL27525272 | 0.89 | OPRM1 (0.51) | HDAC8HRH3GHSRCTSDITGB3 | |
| SCHEMBL4404121 | 0.87 | HDAC8 (0.48) | HDAC8HRH3GHSRCTSDTACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110286923-A1 | NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES | Fundacion de la Communidad Valenciana Centro de Investigacion principe felipe (ES) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110286923-A1 | NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES | VEGFA, FLT4, FLT1 | HDAC8 805/4885HRH3 2845/4885GHSR 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.